All In Biotech

Drug Trial Radar · NCT04877522

Asciminib Roll-over Study

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

347

Planned (sponsor's estimate)

Start

Aug 30, 2022

Primary completion

Aug 30, 2030

Study completion Aug 30, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 7 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

Conditions

  • Chronic Myelogenous Leukemia
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

  • Asciminib single agentDrug

    Taken orally, twice daily (BID) or once daily (QD), in fasting state

  • ImatinibDrug

    Taken orally, once daily, in the morning with low-fat meal

  • NilotinibDrug

    Taken orally, twice daily, on an empty stomach

  • BosutinibDrug

    Taken orally, once daily, with food

  • DasatinibDrug

    Taken orally, once daily in a fasted state, 1 or 2 hours before a meal

  • Asciminib single agent pediatric formulationDrug

    Pediatric participants receive a body weight adjusted dose of 1.3 mg/kg of pediatric film coated granules with food twice daily (b.i.d.) or 2.6 mg/kg once daily (q.d.) in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: 8 years

Locations

88 sites in 29 countries. Site status is shown where the registry gives one.

  • Michigan Med University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Washington University School Of Medicine-Siteman Cancer Ctr

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • Oncology Hematology Care Inc

    Cincinnati, Ohio · Recruiting

  • Oregon Health Sciences University

    Portland, Oregon · Active not recruiting

  • Texas Oncology

    Dallas, Texas · Recruiting

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Novartis Investigative Site

    Capital Federal, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Graz, Austria · Recruiting

  • Novartis Investigative Site

    Vienna, Austria · Recruiting

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil · Completed

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Completed

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Completed

  • Novartis Investigative Site

    Varna, Bulgaria · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Beijing, China · Active not recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Active not recruiting

  • Novartis Investigative Site

    Shenyang, China · Recruiting

  • Novartis Investigative Site

    Tianjin, China · Recruiting

  • Novartis Investigative Site

    Chongqing, Chongqing Municipality, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Recruiting

  • Novartis Investigative Site

    Zhengzhou, Henan, China · Recruiting

  • Novartis Investigative Site

    Wuhan, Hubei, China · Recruiting

  • Novartis Investigative Site

    Changchun, Jilin, China · Recruiting

  • Novartis Investigative Site

    Xian, Shanxi, China · Recruiting

  • Novartis Investigative Site

    Chengdu, Sichuan, China · Completed

  • Novartis Investigative Site

    Brno, Czechia · Recruiting

  • Novartis Investigative Site

    Ostrava, Poruba, Czechia · Recruiting

  • Novartis Investigative Site

    Copenhagen, Denmark · Completed

  • Novartis Investigative Site

    Bordeaux, France · Recruiting

  • Novartis Investigative Site

    Lyon, France · Recruiting

  • Novartis Investigative Site

    Marseille, France · Recruiting

  • Novartis Investigative Site

    Nantes, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, France · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.